Friday, January 10, 2020
New U.K. Organization Partnership to Accelerate HL Therapy Development
Hearing Medicines Discovery Syndicate, launched by the charity Action on Hearing Loss and Medicines Discovery Catapult, will bring together U.K. expertise and infrastructure in hearing research, therapeutic discovery, and development to fast-track the development of hearing therapeutics. The syndicate will offer a broad range of support to companies new to the field and academic groups with limited experience in drug discovery and clinical development, such as by helping them forge links with experts in hearing research, clinical trial design, and cell and gene therapies and by connecting them with licensing and partnership opportunities, clinical trial delivery infrastructure, market intelligence, and patient insight. The Syndicate will work with the National Institute for Health Research (NIHR) through its Biomedical Research Centres (BRC) with expertise in hearing research from University College London Hospitals BRC, Nottingham BRC and Manchester BRC, and the Cell and Gene Therapy Catapult. Dr Ralph Holme, the executive director of research at Action on Hearing Loss, says, "People with hearing loss tell us that being able to hear well would transform their lives. Our initiative will help bring life-changing treatments to people with hearing loss and tinnitus faster."